FDA Clears a Transplant Therapy Built to Cut Chronic GVHD From 44% to 13%
The FDA approved Tregzi, Orca Bio's engineered cell therapy, after a 187-patient trial found it cut moderate-to-severe chronic graft-versus-host disease from 44% with standard transplants to 13%. The tradeoff patients now face

Follow